|
| 36459255 | Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors. | Target Oncol | 2023 |
| 38047213 | Clinical Factors That Affect Fiducial Tracking in Robotic SABR for Lung Tumors. | Adv Radiat Oncol | 2023 |
| 34844977 | A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors. | Clin Cancer Res | 2022 |
| 36289011 | Addendum: The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series. | Oncotarget | 2022 |
| 34890832 | Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study. | Lung Cancer | 2022 |
| 32842875 | Chromatin profiling reveals relocalization of lysine-specific demethylase 1 by an oncogenic fusion protein. | Epigenetics | 2021 |
| 34504655 | The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series. | Oncotarget | 2021 |
| 33957901 | A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. | BMC Cancer | 2021 |
| 34088988 | Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM). | Br J Cancer | 2021 |
| 34280171 | Bromodomain and extraterminal domain protein bromodomain inhibitor based cancer therapeutics. | Curr Opin Oncol | 2021 |
| 32179633 | A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors. | J Immunother Cancer | 2020 |
| 32649682 | The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer. | PLoS One | 2020 |
| 32812320 | Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study. | Oncologist | 2020 |
| 30301863 | Histone Deacetylase Inhibition Has Targeted Clinical Benefit in <i>ARID1A</i>-Mutated Advanced Urothelial Carcinoma. | Mol Cancer Ther | 2019 |
| 30204534 | Development of High-Throughput Screening Assays for Inhibitors of ETS Transcription Factors. | SLAS Discov | 2019 |
| 31216701 | Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life. | Cancers (Basel) | 2019 |
| 31187169 | The effects of lapatinib on cardiac repolarization: results from a placebo controlled, single sequence, crossover study in patients with advanced solid tumors. | Cancer Chemother Pharmacol | 2019 |
| 31296231 | Improved respiratory motion tracking through a novel fiducial marker placement guidance system during electromagnetic navigational bronchoscopy (ENB). | Radiat Oncol | 2019 |
| 31575541 | First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. | Cancer Discov | 2019 |
| 30302599 | Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancer. | Invest New Drugs | 2019 |
| 28800141 | Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis. | J Clin Pharmacol | 2018 |
| 29997151 | Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response. | Mol Cancer Ther | 2018 |
| 29848605 | Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> Alterations. | Cancer Discov | 2018 |
| 30006429 | Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2018 |
| 30006428 | Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2018 |
| 29581250 | LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. | Proc Natl Acad Sci U S A | 2018 |
| 29691300 | Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study. | Clin Cancer Res | 2018 |
| 29632055 | NCCN Guidelines Insights: Colon Cancer, Version 2.2018. | J Natl Compr Canc Netw | 2018 |
| 29515779 | Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cells. | Oncotarget | 2018 |
| 28783865 | A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma. | J Clin Pharmacol | 2018 |
| 27853996 | A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan. | Invest New Drugs | 2017 |
| 28363909 | A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic <i>BRAF</i>-Mutant Colorectal Cancer. | Cancer Discov | 2017 |
| 28275037 | Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2017 |
| 29150397 | Fragment-based design, synthesis, biological evaluation, and SAR of 1H-benzo[d]imidazol-2-yl)-1H-indazol derivatives as potent PDK1 inhibitors. | Bioorg Med Chem Lett | 2017 |
| 28645941 | A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. | Clin Cancer Res | 2017 |
| 28899363 | A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. | BMC Cancer | 2017 |
| 26897615 | Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation. | Invest New Drugs | 2016 |
| 27681579 | Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors. | Cancer Chemother Pharmacol | 2016 |
| 27744565 | A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors. | Cancer Chemother Pharmacol | 2016 |
| 27392790 | Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours. | Cancer Chemother Pharmacol | 2016 |
| 27480105 | GFI1 functions in transcriptional control and cell fate determination require SNAG domain methylation to recruit LSD1. | Biochem J | 2016 |
| 27269937 | Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. | J Clin Oncol | 2016 |
| 27349498 | Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells. | Prostate Cancer Prostatic Dis | 2016 |
| 27338857 | The value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancers. | Semin Cell Dev Biol | 2016 |
| 26719074 | A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin. | Cancer Chemother Pharmacol | 2016 |
| 26951200 | SUMOylation Regulates Growth Factor Independence 1 in Transcriptional Control and Hematopoiesis. | Mol Cell Biol | 2016 |
| 26872892 | The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma. | J Clin Pharmacol | 2016 |
| 26973324 | Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. | Lancet Oncol | 2016 |
| 25377157 | A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function. | Cancer Chemother Pharmacol | 2015 |
| 26504410 | Panobinostat for the treatment of multiple myeloma: the evidence to date. | J Blood Med | 2015 |